Tenet Healthcare enters the back half of August with bulls firmly in charge — options traders have made their most aggressive shift toward calls in months, short sellers have cut exposure at a record pace, and the Street has spent the past month hiking price targets almost uniformly upward.
The options signal is the sharpest of the three. The put/call ratio dropped to 0.95 on August 25, nearly three standard deviations below its 20-day average of 1.31. For a stock that spent all of July and most of August with a PCR above 1.38, this is a meaningful break. Call buyers have decisively outnumbered put buyers for the first time in the trailing data window, suggesting investors are positioning for further upside rather than hedging against a pullback.
Short positioning tells a consistent story. Short interest as a percentage of the float has fallen to 3.0% — down 31.8% over the past month and down nearly 15% in a single session on August 25 alone, the steepest one-day drop in the current data window. The absolute level remains modest, so this is not a squeeze story. It is a covering story: bears who built exposure above 4% of float in mid-July have been unwinding steadily, and that unwind accelerated sharply this week. Borrow conditions reflect this ease — availability is extraordinarily loose at roughly 3,800% of short interest, meaning there are far more shares available to lend than there are shorts in the market. Cost to borrow is statistically anomalous: it registered a 490% weekly jump in percentage terms, but only to 0.31%, a level that remains firmly in "low" territory. The week-over-week arithmetic is exaggerated by an unusually depressed base reading of 0.05% on August 18. There is no meaningful squeeze pressure in the lending market.
The Street is onside. Following the Q2 print in late July — which produced a 22% single-day gain and a 28% five-day move — analysts moved in near-unison to raise targets. Wells Fargo lifted to $281, Truist to $290, Guggenheim to $283, RBC to $283, and Morgan Stanley to $274, all within days of the release. UBS carried the highest conviction, raising to $308. The consensus mean sits at $282, roughly in line with the current price of $271.88, which closed down 2.4% on August 25 — a modest giveback after a 16.6% one-month rally. Bulls point to the USPI ambulatory surgery segment as the growth engine: faster-growing, higher-margin, and increasingly visible in its earnings contribution. Bears flag a specific risk: the expiration of pandemic-era insurance subsidies threatens an estimated $220 million headwind to the Acute segment and $30 million to USPI, with 80-85% of the affected patient population potentially losing coverage. That debate is not new, but it is unresolved. The EPS surprise factor score ranks in the 93rd percentile — the company has been consistently beating expectations — while the analyst recommendation differential ranks in only the 5th percentile, suggesting the broad analyst community is more cautious than the recent target-raise wave implies. The stock trades at roughly 12.8x trailing earnings and 7.7x EV/EBITDA, multiples that have expanded materially over the past month alongside the price move.
Institutional ownership adds texture to the bull-side flow. T. Rowe Price and BlackRock each hold roughly 10.9% of shares. Glenview Capital added 710,812 shares last quarter, Citadel added 1.35 million, and Arrowstreet added just over 1 million — all sizeable active-manager additions into a stock that was then trading meaningfully lower. Boston Partners added nearly 600,000 shares. That cluster of active buying, accumulated at prices well below current levels, helps explain why covering pressure from shorts has not been met with heavy selling on the other side. The one note of caution from the insider register: several executives and directors — including the COO, the CIO, and multiple independent directors — sold shares in late July and early August at prices between $243 and $265. The net 90-day insider flow is a positive $11.5 million, but that reflects the scale of sales rather than any buying cluster. Insider selling into a post-earnings surge is a common pattern, but the breadth of sellers across C-suite and board is worth registering.
What to watch next is whether the options shift sustains: a PCR reading this far below its recent average either marks a durable sentiment change or a one-session anomaly, and how it evolves over the coming days will say something meaningful about whether this week's bullish positioning has legs.
See the live data behind this article on ORTEX.
Open THC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
